Article Information
PubMed
History
- Published online September 9, 2014.
Copyright & Usage
© 2014 Canadian Medical Association or its licensors
Author Information
- Bianca Hemmingsen, MD, PhD1,
- Jeppe B. Schroll, MD2,
- Jørn Wetterslev, PhD1,
- Christian Gluud, DMSc1,
- Allan Vaag, DMSc3,
- David P. Sonne, PhD4,
- Lars H. Lundstrøm, MD, PhD5,
- Thomas Almdal, MD, DMSc4
- 1Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- 2Nordic Cochrane Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- 3Department of Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark
- 4Department of Internal Medicine, Copenhagen University Hospital Gentofte, University of Copenhagen, Hellerup, Denmark
- 5Department of Anaesthesiology, Nordsjællands Hospital, Hillerød, Denmark
- Correspondence to:
Bianca Hemmingsen, biancahemmingsen{at}hotmail.com
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study
- Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
- Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia
- Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study
- Some Doubts About the Mantra on the Deleterious Cardiovascular Effects of Sulfonylureas